Abstract

Objective Describe the Vaccine Safety Datalink’s (VSD) Guillain Barré Syndrome (GBS) surveillance following quadrivalent HPV vaccine (4vHPV) from 2006 through 2015.

Methods Among 4vHPV vaccinated persons aged 9–26, ICD-9 coded GBS was identified in VSD’s electronic data. Medical records were reviewed and adjudicated to confirm GBS. We calculated incidence rates of confirmed GBS within 1–42 days following 4vHPV with a one-sided 95% confidence interval.

Results Following 2,773,185 4vHPV doses, we confirmed 1 case of GBS in a male and no cases among females. The incidence rate of medical record confirmed GBS within 42 days following 4vHPV vaccine was 0.36 cases per million 4vHPV doses administered (1-sided 95% CI 1.71), which was less than the background rate.